PTHS

Pelthos Therapeutics Inc. (PTHS) Economic Moat Analysis (2026)

Invetso Score: 2/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 2.0 (Weak)

No evidence of proprietary brands, patents, or regulated IP that would let PTHS charge meaningfully above peers, so pricing power appears limited.

Negative ROIC and ROCE indicate any intangible advantage is not translating into durable excess returns versus peers.

The absence of disclosed 5-year margin or return history in the provided metrics weakens support for a persistent asset-based moat.

Compared with stronger peers that can defend margins through recognized IP or brand equity, PTHS appears more easily substitutable.

Switching Costs

Score:

A very high cash conversion cycle suggests working-capital intensity rather than customer lock-in, so retention does not appear structurally protected.

Negative ROIC implies customers are not generating enough economic value to create meaningful inertia versus alternative suppliers.

No evidence of contractual lock-in, embedded workflows, or compliance dependence was provided, so switching frictions look low relative to peers.

Compared with peers that benefit from software, data, or regulated-process integration, PTHS shows little sign of durable switching costs.

Network Effects

Score:

No evidence of user, data, or ecosystem feedback loops was provided, so adoption does not appear to compound into peer-leading advantage.

Negative returns suggest scale is not currently reinforcing a self-sustaining platform effect.

Unlike peers with marketplace or platform dynamics, PTHS does not show signs of customer or supplier dependence on a growing network.

The available metrics point to a business that competes on transactions rather than network-driven retention.

Cost Advantage

Score:

Asset turnover of 0.32 indicates low asset productivity, which argues against a structural cost edge versus more efficient peers.

Negative ROIC and ROCE imply operating economics are not strong enough to support lower unit costs or superior margin durability.

The very high cash conversion cycle suggests working capital is a drag, not a source of cost advantage, relative to peers.

No evidence of scale purchasing, process automation, or advantaged input access was provided to support a durable cost edge.

Efficient Scale

Score:

The provided metrics do not indicate a natural monopoly or capacity-constrained market where one or two players can profitably dominate.

Negative returns suggest PTHS is not yet capturing the economics typically associated with efficient-scale protection versus peers.

No evidence of regulatory barriers, exclusive licenses, or fixed-cost absorption that would limit room for additional competitors was provided.

Compared with peers in industries with high entry barriers, PTHS appears to face a more contestable competitive environment.

Overall Score

Score:

PTHS shows no clear evidence of durable moat drivers in the provided data, and negative ROIC/ROCE plus weak efficiency metrics suggest it is not outperforming peers on pricing power, retention, or structural advantage.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Pelthos Therapeutics Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →